702806008: Ruxolitinib (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Transferase inhibitor\Phosphotransferase inhibitor\Protein kinase inhibitor\Protein-tyrosine kinase inhibitor\Janus kinase inhibitor\Ruxolitinib

\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Antineoplastic agent (substance)\Ruxolitinib
\A grouper concept for substances that are used in medicinal products for medical treatment, and also psychoactive substances that have few or no legitimate medical uses or that are not legally available to the person using them.\Pyrazole derivative\Ruxolitinib

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\...

\Azole\Pyrazole and/or pyrazole derivative (substance)\Pyrazole derivative\Ruxolitinib

\Nitrile\Ruxolitinib

\Organic compound\Organic cyclic compound\Heterocyclic compound\Azole\Pyrazole and/or pyrazole derivative (substance)\Pyrazole derivative\Ruxolitinib
\Organic compound\Organic nitrogen compound\Azole\Pyrazole and/or pyrazole derivative (substance)\Pyrazole derivative\Ruxolitinib
\Organic compound\Organic nitrogen compound\Nitrile\Ruxolitinib
\Organic compound\Hydrocarbon\Pyrazole and/or pyrazole derivative (substance)\Pyrazole derivative\Ruxolitinib

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2014. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module

3006149011 Ruxolitinib en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

3006175010 Ruxolitinib (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

1866021000195112 ruxolitinib it Synonym (core metadata concept) Active Entire term case sensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

839091000172115 ruxolitinib fr Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Switzerland NRC maintained Module

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Ruxolitinib	Is a	Protein-tyrosine kinase inhibitor	false	Inferred relationship	Some
Ruxolitinib	Is a	Antineoplastic agent (substance)	true	Inferred relationship	Some
Ruxolitinib	Is a	Janus kinase inhibitor	true	Inferred relationship	Some
Ruxolitinib	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Janus kinase inhibitor (disposition)	true	Inferred relationship	Some
Ruxolitinib	Is a	produit chimique catégorisé selon sa fonction	false	Inferred relationship	Some
Ruxolitinib	Is a	Enzyme inhibitor	false	Inferred relationship	Some
Ruxolitinib	Is a	Nitrile	true	Inferred relationship	Some
Ruxolitinib	Is a	Pyrazole derivative	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
Product containing ruxolitinib (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 5 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 10 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 20 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 15 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 25 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 5 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 5 milligram/1 each conventional release oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 10 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 10 milligram/1 each conventional release oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 20 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 20 milligram/1 each conventional release oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 15 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 15 milligram/1 each conventional release oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 25 milligram/1 each conventional release oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 25 milligram/1 each conventional release oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib phosphate (substance)	Is a	False	Ruxolitinib	Inferred relationship	Some
Product containing precisely ruxolitinib 5 milligram/1 each conventional release oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 10 milligram/1 each conventional release oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 20 milligram/1 each conventional release oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 15 milligram/1 each conventional release oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib 25 milligram/1 each conventional release oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib-containing product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib phosphate (substance)	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Ruxolitinib	Inferred relationship	Some
Ruxolitinib only product	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib only product in oral dose form	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	True	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 5 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib (as ruxolitinib phosphate) 10 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib (as ruxolitinib phosphate) 20 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Ruxolitinib	Inferred relationship	Some	1
Product containing precisely ruxolitinib (as ruxolitinib phosphate) 15 milligram/1 each conventional release oral tablet (clinical drug)	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Ruxolitinib	Inferred relationship	Some	1
Ruxolitinib (as ruxolitinib phosphate) 25 mg oral tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	True	Ruxolitinib	Inferred relationship	Some	1
A characteristic ruxolitinib discontinuation syndrome includes an acute relapse of disease symptoms, splenomegaly, and occasional hemodynamic decompensation. Symptoms can appear from less than 24 hours to up to 3 weeks after the abrupt discontinuation of ruxolitinib.	Associated with	False	Ruxolitinib	Inferred relationship	Some	1
A condition where a patient requires continuous administration of the drug ruxolitinib to manage their symptoms or disease effectively. This dependence can develop because stopping or reducing the dose of ruxolitinib may lead to a relapse or worsening of the condition it was treating, such as myelofibrosis or polycythemia vera.	Causative agent (attribute)	True	Ruxolitinib	Inferred relationship	Some	1

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
3006149011	Ruxolitinib	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3006175010	Ruxolitinib (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
1866021000195112	ruxolitinib	it	Synonym (core metadata concept)	Active	Entire term case sensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
839091000172115	ruxolitinib	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module